Key Points
- Director Quiros Juan Jose Chacon sold 37,500 shares on April 14 at an average of $65.23 for $2,446,125, and after earlier March sales now holds 1,182,504 shares (a 3.07% reduction in his position).
- Establishment Labs beat EPS estimates for the quarter (reported -$0.09 vs. -$0.22 expected) and revenue rose 45.2% year‑over‑year to $64.62 million, but the company remains unprofitable with a -24.19% net margin and negative ROE.
- Shares opened at $64.51 (down ~3.2%), market cap is ~$1.90 billion, and analysts have a consensus rating of "Moderate Buy" with an average price target of $86.86 amid mixed buy/hold/sell opinions.
Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 37,500 shares of the business's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00. Following the sale, the director directly owned 1,182,504 shares in the company, valued at $77,134,735.92. The trade was a 3.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The shares were sold at an average price of $60.08, for a total transaction of $214,786.00.
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.
Establishment Labs Trading Down 3.2%
Shares of ESTA stock opened at $64.51 on Friday. The company's fifty day simple moving average is $67.04 and its two-hundred day simple moving average is $63.96. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a 1 year low of $28.67 and a 1 year high of $83.31. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -37.07 and a beta of 1.08.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business had revenue of $64.62 million for the quarter, compared to analysts' expectations of $63.80 million. During the same quarter in the previous year, the firm posted ($1.19) EPS. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in ESTA. Nantahala Capital Management LLC grew its position in Establishment Labs by 11.1% in the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company's stock worth $80,893,000 after acquiring an additional 197,962 shares in the last quarter. Bamco Inc. NY grew its position in Establishment Labs by 30.2% in the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company's stock worth $48,443,000 after acquiring an additional 274,287 shares in the last quarter. Tyro Capital Management LLC grew its position in Establishment Labs by 1.0% in the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company's stock worth $44,165,000 after acquiring an additional 10,735 shares in the last quarter. William Blair Investment Management LLC grew its position in Establishment Labs by 17.6% in the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company's stock worth $41,709,000 after acquiring an additional 152,299 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company's stock worth $59,145,000 after acquiring an additional 438,206 shares in the last quarter. Institutional investors own 72.91% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on ESTA. Canaccord Genuity Group upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Stephens upped their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Needham & Company LLC upped their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. Wall Street Zen cut shares of Establishment Labs from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Establishment Labs in a report on Friday, March 27th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $86.86.
Get Our Latest Stock Report on ESTA
About Establishment Labs
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
